Member Info for ShearClass

Totally disagree Kevin. No CEO should have to provide a running commentary to the stockmarket. The timelines are clear & have been stated multiple times. Just because some don’t have patience doesn’t mean the company has poor PR.

Cheers Bigmj, will check out SI Capital. Re. Target prices, I think it depends on newsflow - they are active with a lot of different projects & if the market is regularly updated with progress it will aid price discovery. Personally I look at Ilika as a benchmark target within the next 12 months. It’s currently valued at £280m, which would be £8 for AMTE. They are working on solid state batteries but are arguably much further from commercialisation.

Bigmj, I've been researching AMTE for a few days now - there is so much information out there. It's clear that they are a lynchpin in the developing UK (and European) battery market, I've lost count of the number of projects that they are involved in. It's no exaggeration to say this could develop into a mid cap company in the next few years. Out of interest, how did you get to invest pre IPO at 70p?

@aimtitan, quick question for you; do you drive a car looking forwards or backwards?

It's actually comical that AVCT has reached a £640m market cap without even having CE mark authorisation for it's test or any disclosed sensitivity & specificity data beyond 30 individuals.

The below test is more sensitive than anything proposed by AVCT (Ct range of 29-30) and has fully disclosed it's performance data;

https://excaliburhealth.co.uk/news/how-uk-science-and-technology-has-combined-to-produce-a-game-changer-in-lateral-flow-testing/

https://excaliburhealth.co.uk/news/excalibur-rapid-sars-cov-2-antigen-screening-test-granted-mhra-registration-for-mass-population-screening-for-covid-19-in-asymptomatic-and-symptomatic-people/

"The Excalibur Rapid SARS COV-2 Antigen Screening test has equivalent or better sensitivity than any of its competitors, as shown by very extensive studies and expert third party testing. The test demonstrated consistently excellent results when tested independently by Liverpool School of Tropical Medicine, Imperial College, London, a world leading pharmaceutical company and by Boson Diagnostics, China, in collaboration with the renowned National Pathogen Culture Library of Korean Pathogen Resources (NCCP).

A further independent clinical trial at the Catholic University of Korea Incheon St Mary’s Hospital, in a sample size of 659 patients presenting for care, recorded an overall sensitivity of 96%, accurately corresponding to RT-qPCR-confirmed COVID-19 cases. The test has a specificity of 100%."

They also have a manufacturing capability of 3m tests a day...

Why would AVCT win a tender above Excalibur?

LOL at a £14m market cap minnow trying to hold an £800m cap to breach of contract. The very fact they've put it in the RNS suggests there are problems behind the scenes. I think this goes all the way back to the 0.4p level - they are reliant on IAMGOLD who it seems have better priorities.

@Samdb, not sure where you see a classic bowl formation at this stage, it needs to form the base of the bowl over at least a month first. I’d say it looks like a classic double top pattern + a head and shoulders, both are bearish technical patterns and the price is also below all moving averages apart from the 200 day.

The market is currently saying; prove to me that last year wasn’t a one off. Until they communicate expectations I see more downside than upside. I think they would have been in a quandary at the end of January update; set a realistic target for 2021 of say £100m EBITDA and watch the price sell off or go for it and say we can beat 2020 and potentially set themselves up for a fail. Lose lose situation?

It does amaze me that we still have zero clarity on US sales though, that is a weird one.

"Key positive - they say its worth 9p post placing!"
http://www.allenbycapital.com/research/research-nfx_4_1446050680.pdf

What a load of tosh, if it's worth 9p then why did they just raise at 2p? Honestly, it's embarrassing 'research'. They have just picked a figure out of thin air and applied a discount rate to it, unbelievable.

Anyone buying here is mad IMO. Ever since the times published that Japan piece 18 months ago this has been a shambolic mess. The fact the former CTO thinks it’s ok to sell 5m shares in the open market a few days before a heavily discounted placing is announced sums it up. He likely received at least 2.7p a share whilst at the same time placees were paying 2p.

As for directors putting in a few K, does nobody ever consider they could simply award themselves a bonus in this months payroll and use that to satisfy the cost of the shares? It’s just as likely to be the companies money than their own.

Right now NCYT are in the same phase as they were from June - early September last year when it fell off the highs of £5 and all the way back to £2.20 at one stage. It then slowly worked it way back up before the fireworks started with the half year financials. At present the share price is heading back to the long term support line that is sat on for those 3 months last year. This sits at £5.50 and it feels inevitable that the price will get back there unless there is a material contract RNS. There could also be turbulence from Vatel, who have over 1m shares unlocking at the end of March. Once financials are released in June I suspect a re-rate will occur as the value becomes blatant again to all and sundry.

@daddyaim, agree with your comments. I see a double bottom around 16p here, maybe lower - I don’t think they’ve raised anywhere near enough to roll out properly in the US. £75m and I’d have thought differently.

Yep, the way this is moving it is clear that big news is imminent - as others have said the market cap remains tiny versus peers. Interested to see what they land!

Urraca, they are all different - but comps vs SBI, GDR and the early stages of NCYT are relevant, a decent government contract here and this will hit £100m cap I would think so around 12-15p

This could get interesting with only 51m shares in issue...

I think the main challenge they encountered was related to the magnetic separation of tantalum & tin ore, this is mentioned in their recent proactive videos. Let us know what they come back with though!

@Jimbo66, we have 95k tons of tin & 6k tons of tantalum contained in the same ore, so the ratio should be around 1t for every 15t of tin. I.e. around 4t a month at current production levels. However the selling price is around $150k/t

https://www.metalary.com/tantalum-price/ has a decent history of tantalum prices which got to $330k/t back in 2011...

It’s a huge bonus, for context Tirupati Graphite are presently valued at £70m cap and *may* have revenue of £700k a month by the end of this year pending a successful ramp up of graphite production. We should be over double this & have a much more valuable in ground resource.

Then after Tantalum we have 450k tons of Lithium by product to get after... this is a real diamond that is currently loitering in the AIM rough.

Good article from last year about battery developments in the 2020's, interesting in that it didn't envisage sulphur based cathodes until late in the decade. Superior energy density is flagged which we have demonstrated already.

https://www.automotiveworld.com/articles/riding-the-waves-electric-vehicle-battery-materials-of-the-2020s/

The nice thing here is there are multiple ongoing projects, which mitigates the risk whilst at the same time increases the chance of them hitting the jackpot.

I've bought in here this morning as there is continued progress on many fronts... However, to me that Cenkos note clearly says hundreds per KG not hundreds of thousands? Either way, I can only see the market cap increasing here with their refreshing goal of having 'more patents than employees'. So much potential newsflow in the months / years ahead & it only needs a couple of their patented ideas to be successful to transform an £88m cap...

Made a token purchase at 215p, about a fifth of what I wanted to get. Will add once the spin off holders sell there shares in the coming days / weeks, anything around 200p seems decent value, but who knows in the current madness.

Yes that is an additional good point - 20% is significantly more attractive now than back then. I posted mainly as it’s a very good technical piece about IRR’s but also to out Panda1 as a b*ll**** merchant.